MA39743A - Fumarate de diméthyle et régimes de vaccination - Google Patents

Fumarate de diméthyle et régimes de vaccination

Info

Publication number
MA39743A
MA39743A MA039743A MA39743A MA39743A MA 39743 A MA39743 A MA 39743A MA 039743 A MA039743 A MA 039743A MA 39743 A MA39743 A MA 39743A MA 39743 A MA39743 A MA 39743A
Authority
MA
Morocco
Prior art keywords
dimethyl fumarate
vaccination regimens
administering
subject
dose
Prior art date
Application number
MA039743A
Other languages
English (en)
Inventor
Vissia Viglietta
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA39743A publication Critical patent/MA39743A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un procédé pour traiter ou prévenir une maladie ou un trouble (par exemple, ms) chez un sujet en ayant besoin, comprenant (a) l'administration, au sujet, d'une première dose d'une composition pharmaceutique comprenant un agent de fumarate (par exemple, dmf) pendant une première période de dosage ; (b) l'administration d'un vaccin ; et (c) l'administration, au sujet, d'une seconde dose de la composition pharmaceutique pendant une seconde période de dosage.
MA039743A 2014-03-14 2015-03-13 Fumarate de diméthyle et régimes de vaccination MA39743A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461953259P 2014-03-14 2014-03-14

Publications (1)

Publication Number Publication Date
MA39743A true MA39743A (fr) 2017-01-18

Family

ID=52737422

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051730A MA51730A (fr) 2014-03-14 2015-03-13 Fumarate de diméthyle et régimes de vaccination
MA039743A MA39743A (fr) 2014-03-14 2015-03-13 Fumarate de diméthyle et régimes de vaccination

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA051730A MA51730A (fr) 2014-03-14 2015-03-13 Fumarate de diméthyle et régimes de vaccination

Country Status (6)

Country Link
US (5) US10391160B2 (fr)
EP (2) EP3650042A1 (fr)
CA (1) CA2942690A1 (fr)
MA (2) MA51730A (fr)
MX (2) MX389474B (fr)
WO (1) WO2015138917A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3650042A1 (fr) 2014-03-14 2020-05-13 Biogen MA Inc. Fumarate de diméthyle et régimes de vaccination
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
EP3250198A1 (fr) * 2014-12-04 2017-12-06 Biogen MA Inc. Régime de traitement de la sclérose en plaques utilisant du fumarate de diméthyle
CA3182369A1 (fr) * 2020-05-06 2021-07-22 Imcyse Sa Polytherapie pour le traitement de maladies associees au fumarate
CN117320710A (zh) * 2020-05-06 2023-12-29 易姆赛斯股份公司 用于富马酸酯相关疾病的组合治疗
US20230233500A1 (en) * 2020-06-11 2023-07-27 University Of Massachusetts Gasdermin D (GSDMD) Succination for the Treatment of Inflammatory Disease
CN117337192A (zh) * 2021-03-25 2024-01-02 加州大学董事会 用于抑制和治疗病毒感染的组合物和方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
CN114146081A (zh) 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
EP3650042A1 (fr) 2014-03-14 2020-05-13 Biogen MA Inc. Fumarate de diméthyle et régimes de vaccination
AU2015328676B2 (en) 2014-10-08 2017-07-20 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
WO2017040272A1 (fr) 2015-08-31 2017-03-09 Banner Life Sciences Llc Formes posologiques d'ester de fumarate
WO2017151184A1 (fr) 2016-02-29 2017-09-08 Banner Life Sciences Llc Formes posologiques d'ester de fumarate
US10523918B2 (en) 2017-03-24 2019-12-31 Samsung Electronics Co., Ltd. System and method for depth map

Also Published As

Publication number Publication date
US20200360501A1 (en) 2020-11-19
US10994003B2 (en) 2021-05-04
CA2942690A1 (fr) 2015-09-17
US20210228701A1 (en) 2021-07-29
EP3116536A1 (fr) 2017-01-18
MX2022000746A (es) 2022-02-14
MA51730A (fr) 2020-12-16
MX389474B (es) 2025-03-20
WO2015138917A1 (fr) 2015-09-17
US20190247485A1 (en) 2019-08-15
MX2016012052A (es) 2017-04-27
US20220072117A1 (en) 2022-03-10
EP3650042A1 (fr) 2020-05-13
US20170000873A1 (en) 2017-01-05
US10555993B2 (en) 2020-02-11
US10391160B2 (en) 2019-08-27

Similar Documents

Publication Publication Date Title
MX2022000746A (es) Dimetilfumarato y regimenes de vacunacion.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
CY1121566T1 (el) Νευροπροστατευτικο και ενδειξη αυτου
HK1243368A1 (zh) 丁丙诺啡给药方案
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
HK1232465A1 (en) Dimethyl fumarate and vaccination regimens
IL249484A0 (en) Preparation methods for novel creation of biologically safe klh products used in cancer therapy, development of conjugated therapeutics and as challenge agents
IL249483B (en) Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents
NZ725354A (en) Transdermal formulations of pergolide and uses thereof
IN2014DE00822A (fr)